Talecris Biotherapeutics Holdings Corp (NASDAQ:TLCR) has announced the financial results for its three months ended December 31, 2009. The company has filed its 2009 Form 10-k with the US Securities and Exchange Commission (SEC). The full financial report is available for review at www.sec.gov.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Talecris reported a net revenue decrease of 2.8% to $390.1 million for the 2009 fourth quarter. The year ago period had net revenue of $401.4 million. The company’s full year net revenue has increased by $158.9 million, versus $1.37 billion for the 2008. 2009’s diluted EPS was $1.50, versus $0.71 for 2008.
Talecris Biotherapeutics Holdings Corp. is a biopharmaceutical company that is a producer and marketer of plasma-derived protein therapies in the world. The Company develops, produces, markets and distributes therapies that help people suffering from conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns. The Company’s largest product, Gamunex Immune Globulin Intravenous (Human), is one of the products in the intravenous immune globulin (IGIV) market. Its second largest product, Prolastin Alpha 1 Proteinase Inhibitor (Human), was granted orphan drug status and has a 71% share of sales in the United States, a 78% share of sales in the European Union and brand recognition within the alpha-1 proteinase inhibitor (A1PI) category. In June 2007, it acquired three additional plasma collection centers from International BioResources, L.L.C. (IBR).
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
